Physician profile
Amanda Abou Ezzi
NPI 1285093641
$2,828.28
in general payments reported to CMS, 2019-2025
22 companies · $209 in 2025
The $209 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $277 · 2020: $247 · 2021: $517 · 2022: $524 · 2023: $550 · 2024: $505 · 2025: $209.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,264.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,263.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $870.65 | 2019-2025 | Bexsero, Pediarix, Rotarix |
| Kaleo, INC. | $248.89 | 2020-2024 | Auvi-Q |
| Corium, LLC | $246.00 | 2023-2025 | Azstarys, Azstarys |
| Tris Pharma INC | $238.99 | 2020-2024 | Dyanavel Xr |
| Pfizer INC. | $212.82 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $193.69 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $192.64 | 2019-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Abbvie INC. | $107.48 | 2021-2022 | |
| Neos Therapeutics, Lp | $73.28 | 2021-2025 | Cotempla Xr-Odt |
| Vertical Pharmaceuticals, LLC | $67.21 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $61.92 | 2024-2025 | |
| Seqirus USA INC | $58.94 | 2022-2024 | Flucelvax Quadrivalent, Flucelvax |
| Genentech USA, INC. | $58.02 | 2019-2022 | |
| Oxford Immunotec USA INC | $28.84 | 2020 | |
| Shire North American Group INC | $27.00 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adlon Therapeutics L.P. | $26.35 | 2020-2021 | |
| Ultragenyx Pharmaceutical INC. | $24.60 | 2023 | |
| Aytu Biopharma, INC. | $24.44 | 2021-2022 | |
| Ars Pharmaceuticals Operations, INC. | $21.28 | 2025 | Neffy |
| Phadia US INC. | $15.63 | 2025 | Immunocap |
| Supernus Pharmaceuticals, INC. | $15.53 | 2021 | |
| Covis Pharma Gmbh | $14.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Abou Ezzi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.